Buscar
11/02/2025
Radiation exposure using leaded versus regular latex surgical gloves in endourological procedures: a prospective comparative study
Emiliani, E, Bravo-Balado, A, Ruiz-Martinez, A, Giron-Nanne, I, Fontanet, S, Verri, P, Sanchez-Puy, A, Kanashiro, AK, Skolarikos, A, Somani, B, Traxer, O, Sanchez-Martin, F, Millan, F, Angerri, O. Radiation exposure using leaded versus regular latex surgical gloves in endourological procedures: a prospective comparative study. Urolithiasis. 2025; 53(1)DOI:10.1007/s00240-024-01676-y. PMID:39932535. IF:2.200(Q2/5D).
11/02/2025
Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic"
Martín-Aguilar, L, Querol, L. Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic". EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32(2)DOI:10.1111/ene.70069. PMID:39931912. IF:3.900(Q1/3D).
10/02/2025
Global Delphi consensus on treatment goals for generalized pustular psoriasis
Barker, JN, Casanova, E, Choon, SE, Foley, P, Fujita, H, Gonzalez, C, Gooderham, M, Marrakchi, S, Puig, L, Romiti, R, Thaçi, D, Zheng, M, Strober, B. Global Delphi consensus on treatment goals for generalized pustular psoriasis. BRITISH JOURNAL OF DERMATOLOGY. 2025; 192(4)DOI:10.1093/bjd/ljae491. PMID:39844356. IF:9.600(Q1/1D).
10/02/2025
Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.
Fernandez-Mañas, L, Ortiz, I, Pozas, J, Beland, C, Larkin, J, Moll-Febrer, A, González-Aguado, L, Beltran, JS, Anguera, G, Navarro, N, Rodriguez-Vida, A, Novella, SR, Sierra, M, Carrasco, A, González, NS, Yonamine, EPM, Maeso, IG, Figols, M, Alcalá, MM, Reig, O. Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.483. PMID:. IF:41.900(Q1/1D).
10/02/2025
Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.
Rioja, P, Passarella, C, Angel, M, Valderrama, W, Bosma, F, Anguera, G, Gomez, V, Ruiz-Granados, A, Plata, D, Laguado, MIZ, Orta-Ruiz, A, Gandur-Quiroga, MN, Bourlon, MT, Grande, E, Manneh, R, Molina-Cerrillo, J, Maroto-Rey, P, Sade, JP, Castellano, D. Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.502. PMID:. IF:41.900(Q1/1D).
10/02/2025
Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.
Lista, AGD, Romero-Laorden, N, Gajate, P, Orta-Ruiz, A, Jiménez, JGD, Miranda, MJ, Estévez, SV, Molins, C, Pernaut, C, Cordero, MG, Fernández, O, Sánchez, JG, Maeso, IG, Blazquez, PR, Reig, O, Maroto-Rey, P, Martín, A, Ramirez, I, Puente, J. Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.720. PMID:. IF:41.900(Q1/1D).
09/02/2025
Megaprosthesis Infection by Bacteroides fragilis in a Patient With Ewing's Sarcoma: A Case Report and Literature Review
Martínez-Ysasis, Y, Simonetti, AF, Navarro, F. Megaprosthesis Infection by Bacteroides fragilis in a Patient With Ewing's Sarcoma: A Case Report and Literature Review. Clinical Case Reports. 2025; 13(2)DOI:10.1002/ccr3.70185. PMID:39931721. IF:(Q/D).
07/02/2025
Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness
Cardoner, N, Gutiérrez-Rojas, L, Saiz, P, Lahera, G, alvarez-Mon, MA, Ortega, PA, Pérez-Páramo, M. Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness. Frontiers in Pharmacology. 2025; 16DOI:10.3389/fphar.2025.1483770. PMID:39989902. IF:4.800(Q1/2D).